Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ANX009

Monoclonal antibody · developed by Annexon

Phase 1 Most advanced trial (none active)

ANNX Developer

1 Registered trials

What is ANX009?

ANX009 is a recombinant humanized immunoglobulin G1 Fab fragment studied in lupus nephritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Therapy area: Immunology
Developer: Annexon, Inc. (ANNX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05780515	Phase 1	Lupus Nephritis	Completed	ANNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus Nephritis

More from Annexon

ANX105 Phase 1 ANX1502 Phase 1 Tanruprubart Phase 3 Vonaprument Phase 3

Sources

ClinicalTrials.gov NCT05780515

Updated Oct 3, 2026. Something wrong or missing? Report it on the ANNX page.

Follow ANNX, the company behind ANX009

See ANNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANNX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z